Search clinical trials for: MabThera

Total 571 results

University of Copenhagen
Rigshospitalet, Denmark

Completed

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Fatigue | Keratoconjunctivitis Sicca | Primary Sjögren's Syndrome | Xerostomia | Hyposalivation

Denmark
Sociedade Brasileira de Atendimento Integrado ao...

Unknown

Study of Primary Fascial Closure Rate in Patients With Open Abdomen Treated With Abthera Versus Barker Technique

Abdominal Trauma | Abdominal Sepsis | Abdominal Compartment Syndrome
3M

Completed

Open Abdomen Study Comparing ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique

Open Abdomen

United States
University of Calgary
Alberta Health services; 3M

Active, not recruiting

Peritoneal Vacuum Therapy to Reduce Inflammatory Response From Abdominal Sepsis/Injury (SAD)

Intra-abdominal Hypertension | Abdominal Compartment Syndrome

Canada
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
Medical University of Vienna

Terminated

Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission (REDOREM)

Rheumatoid Arthritis | Remission

Austria
Wake Forest University Health Sciences
3M

Completed

ABTHERA ADVANCE™ Use Without Wittman Patch

Necrotizing Pancreatitis

United States
Anna Rockich

Completed

ABRA Abdominal Closure System in Open Abdomen Management (ABRA)

Open Abdomen

United States
Assistance Publique - Hôpitaux de Paris
Hoffmann-La Roche

Completed

Rituximab in Auto-Immune Hemolytic Anemia (RAHIA)

Warm Autoimmune Hemolytic Anemia

France
San Antonio Military Medical Center

Unknown

Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure

Open Abdomen After Damage Control Laparotomy

United States
Medical College of Wisconsin

Recruiting

Delayed Primary Closure Using Negative Pressure Wound Therapy

Infection Abdominal

United States
AtoGen Co. Ltd
ATOGEN AUSTRALIA PTY LTD

Recruiting

Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women

Bacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial Vaginosis

Australia
University of Tennessee
Kinetic Concepts, Inc.

Completed

An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients

Abdominal Trauma
University Hospital, Tours

Completed

Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX) (LYRITUX)

Rheumatoid Arthritis

France
Shandong University

Completed

The Study of Different Dose Rituximab in the Treatment of ITP

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenia

China
Cliniques universitaires Saint-Luc- Université...

Terminated

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy (HYDRIC)

Chronic Lymphocytic Leukemia

Belgium
University Hospital, Rouen

Completed

Effect of Anti CD20 in Pemphigus Desease

Pemphigus

France
The Korean Society of Hematopoietic Stem Cell Transplantation
Hoffmann-La Roche

Unknown

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Steroid-Refractory Chronic GVHD

Korea, Republic of
Karolinska Institutet

Active, not recruiting

RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS (RIDOSE-MS)

Multiple Sclerosis, Relapsing-Remitting

Sweden
Hoffmann-La Roche

Completed

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CaLLypso)

Lymphocytic Leukemia, Chronic

Greece
Hoffmann-La Roche

Completed

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Off-Label Use

Spain, France, Italy, United Kingdom, Germany
University Hospital, Tours
Roche Pharma AG; French Innovative Leukemia Organisation

Completed

Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia (LLC2007SA)

Leukemia

France
Anders Svenningsson
Västerbotten County Council, Sweden

Completed

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)

Progressive Multiple Sclerosis

Sweden
Hoffmann-La Roche

Completed

Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis (RITAM)

Rheumatoid Arthritis

Serbia
Hoffmann-La Roche

Completed

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent

Rheumatoid Arthritis

Romania
Fundación Pública Andaluza Progreso y Salud
Ministry of Health, Spain

Terminated

Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy (RITULUP)

Lupus Nephritis

Spain
Hoffmann-La Roche

Completed

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Korea, Republic of
Hoffmann-La Roche

Completed

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Granulomatosis With Polyangiitis

United States, Canada, United Kingdom, Germany, Italy, Serbia, Turkey, France
Hoffmann-La Roche

Completed

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Lymphoma, Non Hodgkin

Spain
Hoffmann-La Roche

Completed

An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Germany
Hoffmann-La Roche

Completed

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Lymphoma, Follicular

Hungary
Hoffmann-La Roche

Completed

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Follicular Lymphoma

Serbia
Swiss Group for Clinical Cancer Research

Completed

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

Lymphoma

Switzerland, South Africa, Italy, Brazil, North Macedonia, Serbia, Slovakia
Hannover Medical School
German Federal Ministry of Education and Research

Terminated

Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients (RIACT)

Acute Rejection

Germany
Hoffmann-La Roche

Completed

A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma (REFLECT 2)

Lymphoma, Follicular

Serbia
Hoffmann-La Roche

Completed

Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)

Follicular Lymphoma

France
Royal Liverpool University Hospital
Hoffmann-La Roche; University of Liverpool

Completed

Rituximab in Active Ulcerative Colitis

Ulcerative Colitis

United Kingdom
Eric Matteson
Genentech, Inc.; National Center for Research Resources (NCRR)

Completed

Rituximab in Rheumatoid Arthritis Lung Disease

Rheumatoid Arthritis | Interstitial Pneumonia

United States
Hoffmann-La Roche

Completed

Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

Follicular Lymphoma

Germany
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Lymphoma, Follicular

Spain, Sweden, Canada, Mexico, Czech Republic, France, Switzerland, Australia, Israel, Korea, Republic of, United Kingdom, Italy, Brazil, Finland, Russian Federation, Peru, Denmark, Argentina, Poland, Ecuador, Norway, Slovakia
Stanford University

Terminated

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Lymphoma | Non-Hodgkin's Lymphoma

United States
University Hospital, Rouen

Completed

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (Rituximab2)

Bullous Pemphigoid

France
Ostfold Hospital Trust
Oslo University Hospital; South-Eastern Regional Health Authority

Completed

Rituximab as Second Line Treatment for ITP

Immune Thrombocytopenia (ITP)

Norway
Technical University of Munich
University Hospital, Essen; University of Erlangen-Nürnberg; Heinrich-Heine University... and other collaborators

Terminated

Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation (Rituximab 2006)

Renal Transplantation | Transplantation, Kidney | Chronic Allograft Nephropathy | Grafting

Germany
The University of Hong Kong

Active, not recruiting

IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Pemphigus

Hong Kong
Archigen Biotech Limited

Completed

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Korea, Republic of, Hungary, Poland, Czechia, Spain, Bosnia and Herzegovina, Bulgaria, Germany, India, Mexico
Hoffmann-La Roche

Completed

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Non-Hodgkin's Lymphoma

Italy
Hoffmann-La Roche

Completed

An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

Rheumatoid Arthritis

Finland
Astellas Pharma Inc

Completed

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Non-Hodgkin's Lymphoma

United States, France, Spain, United Kingdom

Search clinical trials for: MabThera

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations